Jinhai Medical Technology And 2 Other Noteworthy Picks

Jinhai Medical Technology And 2 Other Noteworthy Picks

As global markets react to various economic developments, the Asian stock landscape continues to capture investor interest with its dynamic shifts and opportunities. Penny stocks, a term that may seem outdated, still hold relevance as they often represent smaller or newer companies with potential for growth at lower price points. By focusing on those with strong financials and clear growth trajectories, investors can uncover hidden gems within this sector.

Name

Share Price

Market Cap

Financial Health Rating

Food Moments (SET:FM)

THB3.86

THB3.81B

★★★★★☆

JBM (Healthcare) (SEHK:2161)

HK$3.00

HK$2.44B

★★★★★★

Lever Style (SEHK:1346)

HK$1.48

HK$915.41M

★★★★★★

TK Group (Holdings) (SEHK:2283)

HK$2.47

HK$2.06B

★★★★★★

CNMC Goldmine Holdings (Catalist:5TP)

SGD0.765

SGD310.05M

★★★★★☆

T.A.C. Consumer (SET:TACC)

THB4.92

THB2.95B

★★★★★★

Yangzijiang Shipbuilding (Holdings) (SGX:BS6)

SGD3.06

SGD12.04B

★★★★★☆

Livestock Improvement (NZSE:LIC)

NZ$0.95

NZ$135.23M

★★★★★★

Rojana Industrial Park (SET:ROJNA)

THB4.72

THB9.54B

★★★★★☆

BRC Asia (SGX:BEC)

SGD4.05

SGD1.11B

★★★★★★

Click here to see the full list of 985 stocks from our Asian Penny Stocks screener.

Here’s a peek at a few of the choices from the screener.

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Jinhai Medical Technology Limited is an investment holding company offering minimally invasive surgery solutions, medical products, and related services in the People’s Republic of China and Singapore, with a market cap of HK$2.96 billion.

Operations: The company generates revenue of SGD 14.82 million from Singapore and SGD 19.83 million from the People’s Republic of China.

Market Cap: HK$2.96B

Jinhai Medical Technology has faced increasing financial challenges, reporting a net loss of SGD 10.25 million for the first half of 2025, with revenue declining to SGD 14.53 million from SGD 25.94 million the previous year. The company’s debt to equity ratio has risen to 41.6% over five years, though its short-term assets exceed liabilities by SGD 3.5 million, suggesting some balance sheet resilience. Despite an experienced board and management team, high volatility in share price and reduced cash runway underscore the risks associated with this investment amidst ongoing unprofitability and declining earnings trajectory in recent years.

SEHK:2225 Debt to Equity History and Analysis as at Sep 2025
SEHK:2225 Debt to Equity History and Analysis as at Sep 2025

Simply Wall St Financial Health Rating: ★★★★★★

link